Upstream Bioprocessing Flashcards
1
Q
What are the products of traditional bioprocessing?
A
- Antibiotics
- Vaccines / viruses
- Antibodies
- Recombinant therapeutic proteins (i.e. MAb) (Global market worth £30 billion/year)
2
Q
What are the applications for (Stem) Cell bioprocessing?
A
- Cells and Tissues
- Banking/Drug screening programmes
- Larger scale healthcare applications →Stem cell therapies (potential to cure diseases, not just to treat/address symptoms)
3
Q
Describe bioprocessing complexity
A
4
Q
Draw a diagtam of therapeutic agent production
A
5
Q
Draw a table of cell requirements
A
6
Q
Describe the INDUSTRIAL SCALE meaning for biotherapeutics
A
- >10,000 Litres – Monoclonal antibodies (MAbs) and proteins
- 2,000 Litres – Viral vaccines
- 50 Litres – Human mesenchymal stem cells for therapies
(Lawson et al, 2017)
7
Q
Scaled out production
A
8
Q
Scaled Up production
A
9
Q
Advantages of scale-up
A
- Is the current industrial standard.
- It is well established.
- Cost effective.
- Appropriate for Allogeneic approaches
10
Q
Advantages of scale-out
A
- Allows for parallel runs.
- In case of contamination or failure, only minimal loss.
- Appropriate for Autologous approaches.
11
Q
Disadvantages of Scale up
A
- Many engineering challenges (e.g. mixing, gradients, temperature and pH maintenance).
- In case of contamination or failure, maximal loss.
- Equipment scale challenges.
12
Q
Disadvantages of scale-out
A
- Highly laborious unless automation is used.
- Less cost effective.
13
Q
What are the biological and engeineering considerations for scaling up production?
A
- Scale-up is usually the final step of any R&D programme
- Biologists usually don’t fully understand the challenges of a scalable process
- Engineers don’t always understand the biology
- Engineers don’t get involved soon enough
- Scaling up a bioprocess requires important engineering aspects that have to be considered early in the process => DETRIMENTAL effect on the overall manufacturing process
14
Q
Inefficient scale up: Lower economic performance
A
- Lower yield
- Lower capacity
- Lower product quality
15
Q
Inefficient scale up: Operational instability
A
- Mechanical instabilities
- Genetic instability
- Variability
16
Q
Name some planar culture vessels
A
- T-flasks
- Multilayer plates
- Cell factoreies
- Roller bottlesCompacT SelectT– automated cell culture platform